Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

France, Sanofi (NASDAQ:SNY) is a global healthcare company providing therapeutic solutions for diabetes, cardiovascular diseases, rare diseases, oncology, and immunology, alongside established ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.